Sex-related differences in urothelial cell carcinoma of the bladder in Germany.
NMIBC
TCC
UCB
UCC
bladder cancer
gender
sex
urothelial cancer
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
16
1
2019
Statut:
epublish
Résumé
Urothelial cell carcinoma (UCC), also called transitional cell cancer, occurs significantly more often in males than in females. Essential for the prognosis of recovery is depth of infiltration (muscle-invasive or non-muscle invasive) and tumor-differentiation at initial diagnosis. The current study aimed to explore sex-related differences after initial diagnosis of UCC in Germany. We identified patients who underwent transurethral resection of the bladder tumor (TUR-BT). Data were retrospectively analyzed, including TNM classification, histopathological grading, risk group according to the European Association of Urology (EAU), use of photody-namic diagnosis (PDD), and early intravesical chemotherapy (IVC). A total of 539 male and 190 female patients with UCC underwent TUR-BT. Approximately 75% were non-muscle invasive bladder cancer (NMIBC). Females evidenced significantly higher rates of muscle-invasive bladder cancer (MIBC; Females were significantly more likely to suffer from MIBC at the time of first diagnosis. In NMIBC, males showed a significantly higher prevalence of CIS and EAU low-risk NMIBC females showed significantly higher rates of progression. Sex was not associated with recurrence rates in NMIBC. PDD and IVC were equally effective in both sexes. Based on the collected data we suggest to further investigate possible sex differences in UCC with therapeutical impact. Additional prospective multicenter studies are needed to evaluate both sex-related long-term disease courses and effectiveness of therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Urothelial cell carcinoma (UCC), also called transitional cell cancer, occurs significantly more often in males than in females. Essential for the prognosis of recovery is depth of infiltration (muscle-invasive or non-muscle invasive) and tumor-differentiation at initial diagnosis. The current study aimed to explore sex-related differences after initial diagnosis of UCC in Germany.
METHODS
METHODS
We identified patients who underwent transurethral resection of the bladder tumor (TUR-BT). Data were retrospectively analyzed, including TNM classification, histopathological grading, risk group according to the European Association of Urology (EAU), use of photody-namic diagnosis (PDD), and early intravesical chemotherapy (IVC).
RESULTS
RESULTS
A total of 539 male and 190 female patients with UCC underwent TUR-BT. Approximately 75% were non-muscle invasive bladder cancer (NMIBC). Females evidenced significantly higher rates of muscle-invasive bladder cancer (MIBC;
CONCLUSION
CONCLUSIONS
Females were significantly more likely to suffer from MIBC at the time of first diagnosis. In NMIBC, males showed a significantly higher prevalence of CIS and EAU low-risk NMIBC females showed significantly higher rates of progression. Sex was not associated with recurrence rates in NMIBC. PDD and IVC were equally effective in both sexes. Based on the collected data we suggest to further investigate possible sex differences in UCC with therapeutical impact. Additional prospective multicenter studies are needed to evaluate both sex-related long-term disease courses and effectiveness of therapies.
Identifiants
pubmed: 30643456
doi: 10.2147/CMAR.S181532
pii: cmar-11-309
pmc: PMC6314054
doi:
Types de publication
Journal Article
Langues
eng
Pagination
309-316Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
J Urol. 1999 Apr;161(4):1120-3
pubmed: 10081851
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Gend Med. 2008 Dec;5(4):385-94
pubmed: 19108811
Eur Urol. 2009 Aug;56(2):247-56
pubmed: 19409692
BJU Int. 2010 Feb;105(3):300-8
pubmed: 19912200
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
BJU Int. 2013 Jul;112(1):68-73
pubmed: 23320798
Br J Cancer. 2013 Apr 16;108(7):1534-40
pubmed: 23481180
Eur Urol. 2013 Sep;64(3):421-30
pubmed: 23830475
Urol Oncol. 2014 Jan;32(1):40.e23-31
pubmed: 23831109
Eur Urol. 2013 Oct;64(4):624-38
pubmed: 23906669
Br J Cancer. 2013 Sep 17;109(6):1460-6
pubmed: 23982601
BJU Int. 2013 Dec;112(8):1096-104
pubmed: 24053153
Eur J Surg Oncol. 2015 Mar;41(3):368-77
pubmed: 24674298
Cent European J Urol. 2014;66(4):418-22
pubmed: 24757531
Scand J Urol. 2016 Aug;50(4):292-7
pubmed: 27002743
Urol Oncol. 2018 Jan;36(1):8.e17-8.e24
pubmed: 28947304